PLC Systems Inc. (AMEX:PLC) announced today that it will defer the commencement of the U.S. pivotal trial of its RenalGuard™ System in the prevention of Contrast-Induced Nephropathy (CIN). The company continues to support the investigator-sponsored clinical trial now ongoing in Milan, Italy as well as the limited market launch of RenalGuard in Europe, which began in the first quarter of this year, both of which are focused on the CIN prevention market.PLC Systems was mentioned earlier in our Franklin Industry series
Wednesday, July 23, 2008
"We are taking this action now"
FRANKLIN, MA, July 21, 2008 ---